Biological comprehension of this prognostic role has revealed that loss of STK11 impairs the activation of AMP-activated protein kinase (AMPK), consequently allowing activity of the mammalian target of rapamycin (mTOR) [20], ultimately inhibiting cell proliferation, cancer-associated metabolism, and differentiation towards metastatic phenotype [21]. The gene discussed is MTOR; the disease is cancer.